BR9814435A - Novos esteróides antiestrogênicos e composições farmacêuticas associadas - Google Patents

Novos esteróides antiestrogênicos e composições farmacêuticas associadas

Info

Publication number
BR9814435A
BR9814435A BR9814435-9A BR9814435A BR9814435A BR 9814435 A BR9814435 A BR 9814435A BR 9814435 A BR9814435 A BR 9814435A BR 9814435 A BR9814435 A BR 9814435A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
steroids
new
antiestrogenic
compounds
Prior art date
Application number
BR9814435-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Masato Tanabe
Richard H Peters
Wan-Ru Chao
Ling Jong
Original Assignee
Stanford Res Inst Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanford Res Inst Int filed Critical Stanford Res Inst Int
Publication of BR9814435A publication Critical patent/BR9814435A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR9814435-9A 1997-12-24 1998-12-23 Novos esteróides antiestrogênicos e composições farmacêuticas associadas BR9814435A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/998,877 US6054446A (en) 1997-12-24 1997-12-24 Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
PCT/US1998/027406 WO1999033859A2 (en) 1997-12-24 1998-12-23 Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use

Publications (1)

Publication Number Publication Date
BR9814435A true BR9814435A (pt) 2004-08-10

Family

ID=25545637

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814435-9A BR9814435A (pt) 1997-12-24 1998-12-23 Novos esteróides antiestrogênicos e composições farmacêuticas associadas

Country Status (14)

Country Link
US (3) US6054446A (enExample)
EP (4) EP2305694A3 (enExample)
JP (4) JP2001525855A (enExample)
KR (1) KR100464739B1 (enExample)
CN (2) CN101130567B (enExample)
AU (1) AU749597C (enExample)
BR (1) BR9814435A (enExample)
CA (1) CA2281844C (enExample)
DE (2) DE69812433T2 (enExample)
HU (1) HUP0100136A3 (enExample)
IL (1) IL136972A0 (enExample)
NO (1) NO317978B1 (enExample)
RU (1) RU2233288C2 (enExample)
WO (1) WO1999033859A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
DE50016101D1 (de) * 1999-08-13 2011-06-09 Curadis Gmbh Substanzen und mittel zur positiven beeinflussung von kollagen
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
AUPQ342599A0 (en) * 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof
US6784170B2 (en) * 2000-02-11 2004-08-31 Sri International Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one
EP1284272A4 (en) 2000-04-24 2003-09-10 Kyowa Hakko Kogyo Kk ESTRA-1,3,5 (10) -TRIENE DERIVATIVES
WO2001099009A2 (en) * 2000-06-20 2001-12-27 United States Postal Service Systems and methods for electronic message content identification
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
JP2004518637A (ja) * 2000-11-03 2004-06-24 ワシントン・ユニバーシティ 細胞保護活性を有する修飾されたヒドロキシ置換芳香族構造体
AU8838601A (en) * 2000-11-27 2002-06-03 Entremed Inc Antiangiogenic agents
JP2002241395A (ja) * 2001-02-16 2002-08-28 Taiho Yakuhin Kogyo Kk エストラ−４，６−ジエン−３，１７−ジオンの製造方法
EP1450839A4 (en) * 2001-11-06 2009-06-24 Serono Lab METHOD OF TREATING BREAST CANCER THAT MEETS OESTROGENES
IL161630A0 (en) * 2001-11-06 2004-09-27 Applied Research Systems Methods of treating endometreosis
WO2003059931A1 (en) * 2002-01-21 2003-07-24 Akzo Nobel N.V. PROCESS FOR THE PREPARATION OF 7α-METHYLSTEROIDS
DE10307103A1 (de) * 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate
EP1633367A2 (en) 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogenic agents
CA2536946A1 (en) * 2003-08-26 2005-03-03 Board Of Regents, The University Of Texas System Estrogen receptor modulators and uses thereof
WO2005089256A2 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
US20060264413A1 (en) 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
PL1919290T3 (pl) * 2005-07-12 2014-06-30 Ampio Pharmaceuticals Inc Sposoby i produkty do leczenia chorób
TW200740442A (en) * 2005-08-29 2007-11-01 Taiho Pharmaceutical Co Ltd Therapeutic agent for hypertension
US7935838B2 (en) * 2005-10-27 2011-05-03 Sri International Process for production of steroid compound
EP2001482B1 (en) 2006-03-20 2016-08-24 CASI Pharmaceuticals, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
EA022760B1 (ru) 2007-10-16 2016-02-29 Репрос Терапьютикс Инк. Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
EP2554174B1 (en) 2009-06-22 2015-09-02 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
RU2422455C1 (ru) * 2009-10-13 2011-06-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет ДИАЦЕТАТ РАЦЕМИЧЕСКОГО 3,17β-ДИГИДРОКСИ-7α,18-ДИМЕТИЛ-6-ОКСАЭСТРА-1,3,5( 10 ),8(9)-ТЕТРАЕНА, ОБЛАДАЮЩИЙ ОСТЕОПРОТЕКТОРНЫМ, ГИПОХОЛЕСТЕРИНЕМИЧЕСКИМ И АНТИОКСИДАНТНЫМ ДЕЙСТВИЕМ
US8268807B2 (en) * 2010-04-19 2012-09-18 Sri International Compositions and method for the treatment of multiple myeloma
WO2011156908A1 (en) 2010-06-16 2011-12-22 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US20130123222A1 (en) * 2011-11-10 2013-05-16 Sri International, Inc. Synergistic Anti-Cancer Activity of SR16388 with Anti-Mitotic Drugs
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2014009322A (es) 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015179782A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3323417A4 (en) * 2015-07-14 2019-06-05 Nobelpharma Co., Ltd. PARTIAL ESTROGEN RECEPTOR BETA AGONIST WITH ESTROGEN RECEPTOR-ALPHA-INHIBITING EFFECT AND THERAPEUTIC AGENT AGAINST GYNECOLOGICAL DISORDERS THEREOF
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3373967B9 (en) 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
WO2017096025A1 (en) 2015-12-02 2017-06-08 Helix Twelve Pharmaceuticals Corporation, Inc. Norpregnane derivatives for the risk reduction of breast cancer
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN107805247B (zh) * 2017-10-31 2020-09-29 上海长征富民金山制药有限公司 一种用于制备抗肾纤维化药物和/或抗慢性肾病药的β-咔啉化合物的制备工艺及其应用
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE84180C (enExample) *
FR943462A (fr) * 1946-03-08 1949-03-09 Ford Dispositif d'évacuation de l'eau pour glaces de voiture automobile
US2666769A (en) * 1952-09-27 1954-01-19 Searle & Co 17-glycolyl-estradiols
US2840581A (en) * 1956-12-17 1958-06-24 Upjohn Co Carbonyloxy steroids
NL294517A (enExample) * 1962-06-25 1900-01-01
FR1453210A (fr) 1963-05-08 1966-06-03 Roussel Uclaf Nouveaux aminostéroïdes et procédé de préparation
FR3031M (fr) 1963-05-08 1964-12-28 Roussel Uclaf Nouveau médicament notamment pour le traitement de l'hypercholestérolémie et des troubles en résultant.
FR3012M (fr) * 1963-05-13 1964-12-21 Roussel Uclaf Nouveaux médicaments doués notamment d'activité hypocholestérolémiante.
US3271426A (en) * 1963-06-28 1966-09-06 Schering Corp Novel androstane oximino ethers and methods for their manufacture
NL125071C (enExample) * 1963-12-24
FR1512326A (fr) * 1964-03-27 1968-02-09 Roussel Uclaf Nouveaux stéroïdes azotés et procédé de préparation
US3271392A (en) * 1965-09-14 1966-09-06 American Home Prod 17alpha-[3'-furyl]-estrogens
US3318917A (en) * 1965-11-12 1967-05-09 Searle & Co 17alpha-(4-alkoxy-3-buten-1-ynyl)estra-1, 3, 5(10)-triene-3, 17beta-diols and derivatives thereof
US3405147A (en) * 1966-02-25 1968-10-08 Searle & Co 17-phenylaliphatylestra-1, 3, 5(10)-trien-3-ols, 16-dehydro derivatives correspondingand esters thereof
US3398138A (en) * 1966-05-24 1968-08-20 American Home Prod Novel cardenolides and derivatives
US3448126A (en) * 1967-02-27 1969-06-03 Searle & Co 3-oxygenated 19-norpregna-1,3,5(10),17(20)-tetraen-21-als and enol esters thereof
US3536703A (en) * 1968-09-11 1970-10-27 Searle & Co N - (3 - alkoxy - 19 - norpregna - 1,3,5(10),17(20) - tetraen - 21 - yl)amines and derivatives thereof
GB1305752A (enExample) * 1970-03-06 1973-02-07
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
BE787343A (fr) * 1971-08-10 1973-02-09 Hoffmann La Roche Procede pour la preparation de 17-(2-halogenoethylidene)- steroides
FI54128C (fi) * 1972-12-09 1978-10-10 Akzo Nv Foerfarande foer framstaellning av nya 11,11-alkylidensteroider ur oestran- och 19-norpregnanserien med foerbaettrad hormonell verkan
US3859365A (en) * 1973-07-19 1975-01-07 Eastman Kodak Co Production of alkyl-substituted phenols from cyclohexenones
US3946052A (en) * 1975-06-16 1976-03-23 Stanford Research Institute 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity
SU801517A1 (ru) * 1979-06-26 1988-12-30 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе Способ получени 14 @ -оксиандрост-4-ен-3,17-диона
US4705783A (en) * 1985-06-25 1987-11-10 Sri International 9α, 11β-substituted and 11β-substituted estranes
US5274089A (en) * 1985-10-18 1993-12-28 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
WO1987002367A2 (en) * 1985-10-18 1987-04-23 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
DE3741800A1 (de) * 1987-12-07 1989-06-15 Schering Ag 17-halogenmethylen-estratriene
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
DE3925507A1 (de) * 1989-07-28 1991-01-31 Schering Ag 14,17(alpha)-etheno- und ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
ES2112268T3 (es) * 1990-08-14 1998-04-01 Hoechst Marion Roussel Inc Nuevos 19-nor-esteroides que tienen en posicion 11beta una cadena carbonada que comprende una funcion amida, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
DE4132182A1 (de) * 1991-09-24 1993-03-25 Schering Ag 11(beta)-substituierte 14, 17-ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
FR2685332A1 (fr) * 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
BR9306058A (pt) 1992-03-11 1997-11-18 Narhex Ltd Derivados de amina de hidrocarbonetos oxo- e hidroxi- substituidos
TW303299B (enExample) 1993-07-22 1997-04-21 Lilly Co Eli
US5554603A (en) * 1993-09-17 1996-09-10 The United States Of America As Represented By The Department Of Health And Human Services Orally active derivatives of 1,3,5(10)-estratriene
JPH07101977A (ja) * 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5447941A (en) 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5461064A (en) 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5451589A (en) 1993-12-21 1995-09-19 Eli Lilly And Company Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5446053A (en) 1993-12-21 1995-08-29 Eli Lilly And Company Methods of inhibiting dysfunctional uterine bleeding
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5593987A (en) 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US5591753A (en) 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
FR2718138B1 (fr) * 1994-04-01 1996-04-26 Roussel Uclaf Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant.
US5612317A (en) * 1994-08-04 1997-03-18 Holick; Michael F. Method for delivering estrogen
GB9518858D0 (en) * 1995-09-14 1995-11-15 Pharmacia Spa Phenylsubstituted 4-azasteroid fluoroderivatives
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
US5945412A (en) * 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
RU58668U1 (ru) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" Водогрейный котел

Also Published As

Publication number Publication date
JP2007031446A (ja) 2007-02-08
HUP0100136A3 (en) 2002-04-29
DE69812433D1 (de) 2003-04-24
JP2001525855A (ja) 2001-12-11
JP2007269797A (ja) 2007-10-18
NO317978B1 (no) 2005-01-17
WO1999033859A3 (en) 1999-12-23
CA2281844C (en) 2007-06-19
KR20000075580A (ko) 2000-12-15
WO1999033859A9 (en) 1999-09-23
CN1291196A (zh) 2001-04-11
WO1999033859A2 (en) 1999-07-08
NO20003254L (no) 2000-08-21
EP1310509B1 (en) 2008-08-13
US6054446A (en) 2000-04-25
EP1056768B1 (en) 2003-03-19
US20020032181A1 (en) 2002-03-14
RU2233288C2 (ru) 2004-07-27
JP4959276B2 (ja) 2012-06-20
JP4718512B2 (ja) 2011-07-06
EP2305694A3 (en) 2013-04-17
EP1847548A3 (en) 2012-09-12
CN1332974C (zh) 2007-08-22
CA2281844A1 (en) 1999-07-08
CN101130567A (zh) 2008-02-27
US6455517B1 (en) 2002-09-24
AU749597B2 (en) 2002-06-27
EP2305694A2 (en) 2011-04-06
CN101130567B (zh) 2011-11-23
EP1847548A2 (en) 2007-10-24
KR100464739B1 (ko) 2005-01-05
AU749597C (en) 2003-02-20
EP1310509A3 (en) 2004-12-08
US6281205B1 (en) 2001-08-28
DE69812433T2 (de) 2004-02-12
DE69839893D1 (de) 2008-09-25
EP1056768A2 (en) 2000-12-06
NO20003254D0 (no) 2000-06-22
JP3968114B2 (ja) 2007-08-29
HUP0100136A2 (hu) 2001-08-28
IL136972A0 (en) 2001-06-14
JP2007051148A (ja) 2007-03-01
AU2010499A (en) 1999-07-19
EP1310509A2 (en) 2003-05-14

Similar Documents

Publication Publication Date Title
BR9814435A (pt) Novos esteróides antiestrogênicos e composições farmacêuticas associadas
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
WO1996019458A3 (en) Steroid receptor modulator compounds and methods
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
BR0009814A (pt) Processo para tratar de uma doença associada com o receptor-beta estrogênico
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
YU7797A (sh) Kombinovana terapija za osteoporozu
BR9712808A (pt) Indol-3-glioxilamidas n-substituìdas com efeito antiasmático, anti-alérgico e imunossupressor/imunomodulador
FI970526L (fi) Estra-1,3,5(10)-trieenijohdannaiset, niiden valmistusmenetelmät sekä näitä yhdisteitä sisältävät farmaseuttiset koostumukset
DK0402950T3 (da) Behandling af postmenopausale ulemper
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
EE200000050A (et) Ravimkoostised, kasutusvalmis komplektid ja meetodid peaaju neurovaskulaarsete häirete ja lihaspingepeavalu inhibeerimiseks
BR0110208A (pt) Composições e terapias para distúrbios associados com hiperlipidemia
BR0008011A (pt) Agente embranquecedor fluorescente, suapreparação e uso
BR9909486A (pt) Compostos calcilìticos
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
KR960030947A (ko) src SH2 특이성 화합물의 골흡수 질환 치료 용도
BR9812780A (pt) 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio
BR0316070A (pt) Composto, composição farmacêutica, uso de um composto e, método para modular mchr
BR9712307A (pt) Pirazolinonas para o tratamento de potência enfraquecida
BR9806193A (pt) Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL. C07J 41/00, C07J 43/00.

Ipc: A61K 31/56 (2006.01), A61K 31/57 (2006.01), A61K 3

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements